Recently, a breakthrough in HER2-targeted treatment was achieved with therapy utilizing trastuzumab deruxtecan (T-Dxd), which appeared to be effective not only in previously treated HER2-positive breast cancer [9] but also in breast cancer with lower HER2 expression [10]. The gene discussed is ERBB2; the disease is breast carcinoma.